Notable Publications

Investigational New Drugs

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma

Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D

Clinical Cancer Research

Antiangiogenic therapy for glioblastoma: current status and future prospects

Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M

PLOS One

Molecular subtypes of glioblastoma are relevant to lower grade glioma

Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS

Journal of Clinical Oncology

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M

Targeted Oncology

Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept

Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J

Neuro-Oncology

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype

Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF

Neurology

Moving toward molecular classification of diffuse gliomas in adults

Theeler BJ, Yung WK, Fuller GN, De Groot JF

Clinical Cancer Research

High-dose antiangiogenic therapy for glioblastoma: less may be more?

de Groot JF

Oncotarget

Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma

de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger AB

Journal of Clinical Oncology

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY

Clinical Cancer Research

Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept

de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV

Journal of the National Comprehensive Cancer Network

Multigene sets for clinical application in glioma

de Groot JF, Sulman EP, Aldape KD

Neuro-Oncology

Clinical trial end points for high-grade glioma: the evolving landscape

Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY

Neuro-Oncology

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA

Journal of Clinical Oncology

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM

Clinical Cancer Research

Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy

Lucio-Eterovic AK, Piao Y, de Groot JF

Molecular Cancer Therapeutics

Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma

Milano V, Piao Y, LaFortune T, de Groot J